Top

Published in:

01-06-2013 | Macrovascular Complications in Diabetes (PD Reaven, Section Editor)

Exercise and Diabetes-Related Cardiovascular Disease: Systematic Review of Published Evidence from Observational Studies and Clinical Trials

Authors: Robert W. Koivula, Åsa B. Tornberg, Paul W. Franks

Published in: Current Diabetes Reports | Issue 3/2013

Abstract

The cost of treating cardiovascular disease (CVD) and diabetes is enormous and is set to rise in the coming years. Physical inactivity and sedentary behaviors are major risk factors for these diseases and are estimated to account for several million global deaths annually. Lifestyle interventions, particularly those aimed at enhancing physical activity levels, have a substantial favorable impact on diabetes progression in people at high risk of the disease. Although observational studies and small intervention studies suggest that physical activity might also prevent CVD in people with diabetes, this is not supported by the results of larger randomized controlled trials of lifestyle intervention. The purpose of this review is to provide an overview of the published studies focused on the role of physical activity in CVD prevention in persons with diabetes, and to discuss the implications of these studies’ findings. Our review identified almost 100 studies published in the past decade relevant to this topic.

• Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;380:219–29. This paper estimates the impact of physical inactivity on global morbidity and premature mortality.PubMedCrossRef

World Health Organization. The global burden of disease: 2004 update. World Health Organization, Geneva. 2008. http://www.who.int/evidence/bod. Accessed January 17, 2013.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.PubMedCrossRef

Bloom DE, Cafiero ET, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S. The Global Economic Burden of Noncommunicable Diseases. Geneva: World Economic Forum; 2011.

• Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34. doi:10.1056/nejm199807233390404. One of the first major studies that impacted policy that showed that people with diabetes are at high risk of coronary heart disease.PubMedCrossRef

Fox CS, Coady S, Sorlie PD, D’Agostino Sr RB, Pencina MJ, Vasan RS, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation. 2007;115:1544–50. doi:10.1161/circulationaha.106.658948.PubMedCrossRef

Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3:463–524.PubMedCrossRef

Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14:575–85. doi:10.1016/j.cmet.2011.07.015.PubMedCrossRef

Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50. doi:10.1056/nejm200105033441801.PubMedCrossRef

10.

Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286:1218–27.PubMedCrossRef

11.

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403. doi:10.1056/NEJMoa012512.PubMedCrossRef

12.

Batty GD, Shipley MJ, Marmot M, Smith GD. Physical activity and cause-specific mortality in men with type 2 diabetes/impaired glucose tolerance: evidence from the Whitehall study. Diabet Med. 2002;19:580–8.PubMedCrossRef

13.

Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation. 2007;116:2110–8. doi:10.1161/circulationaha.107.729939.PubMedCrossRef

14.

• Helmrich SP, Ragland DR, Leung RW, Paffenbarger Jr RS. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med. 1991;325:147–52. doi:10.1056/nejm199107183250302. A landmark paper underscoring the protective nature of physical activity in type 2 diabetes.PubMedCrossRef

15.

• Manson JE, Rimm EB, Stampfer MJ, Colditz GA, Willett WC, Krolewski AS, et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet. 1991;338:774–8. A landmark paper underscoring the protective nature of physical activity in type 2 diabetes.PubMedCrossRef

16.

Hu FB, Sigal RJ, Rich-Edwards JW, Colditz GA, Solomon CG, Willett WC, et al. Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study. JAMA. 1999;282:1433–9.PubMedCrossRef

17.

Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790–7. doi:10.1056/NEJMoa010492.PubMedCrossRef

18.

Seibaek M, Vestergaard H, Burchardt H, Sloth C, Torp-Pedersen C, Nielsen SL, et al. Insulin resistance and maximal oxygen uptake. Clin Cardiol. 2003;26:515–20.PubMedCrossRef

19.

• Grontved A, Hu FB. Television viewing and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a meta-analysis. JAMA. 2011;305:2448–55. doi:10.1001/jama.2011.812. An important summary paper defining the nature of the relationship between physical activity and sedentary behavior in type 2 diabetes and CVD.PubMedCrossRef

20.

Morais PK, Campbell CS, Sales MM, Motta DF, Moreira SR, Cunha VN, et al. Acute resistance exercise is more effective than aerobic exercise for 24 h blood pressure control in type 2 diabetics. Diabetes Metab. 2011;37:112–7. doi:10.1016/j.diabet.2010.08.008.PubMedCrossRef

21.

•• Ribisl PM, Lang W, Jaramillo SA, Jakicic JM, Stewart KJ, Bahnson J, et al. Exercise capacity and cardiovascular/metabolic characteristics of overweight and obese individuals with type 2 diabetes: the Look AHEAD clinical trial. Diabetes Care. 2007;30:2679–84. doi:10.2337/dc06-2487. The Look AHEAD Study is the most informative randomized clinical trial to date that focuses on the effects of lifestyle intervention on CVD in persons with type 2 diabetes.PubMedCrossRef

22.

•• Sluik D, Buijsse B, Muckelbauer R, Kaaks R, Teucher B, Johnsen NF, et al. Physical activity and mortality in individuals with diabetes mellitus: a prospective study and meta-analysis. Arch Intern Med. 2012:1–11. doi:10.1001/archinternmed.2012.3130. This paper provides new data and meta-analysis of existing data showing that physical activity is favorably associated with mortality in people with type 2 diabetes.

23.

Kadoglou NP, Iliadis F, Angelopoulou N, Sailer N, Fotiadis G, Voliotis K, et al. Cardiorespiratory capacity is associated with favorable cardiovascular risk profile in patients with Type 2 diabetes. J Diabetes Complications. 2009;23:160–6. doi:10.1016/j.jdiacomp.2007.12.008.PubMedCrossRef

24.

Franks PW, Ekelund U, Brage S, Wong MY, Wareham NJ. Does the association of habitual physical activity with the metabolic syndrome differ by level of cardiorespiratory fitness? Diabetes Care. 2004;27:1187–93.PubMedCrossRef

25.

Green S, Askew CD, Walker PJ. Effect of type 2 diabetes mellitus on exercise intolerance and the physiological responses to exercise in peripheral arterial disease. Diabetologia. 2007;50:859–66. doi:10.1007/s00125-006-0587-7.PubMedCrossRef

26.

Iijima K, Iimuro S, Shinozaki T, Ohashi Y, Sakurai T, Umegaki H, et al. Lower physical activity is a strong predictor of cardiovascular events in elderly patients with type 2 diabetes mellitus beyond traditional risk factors: the Japanese Elderly Diabetes Intervention Trial. Geriatr Gerontol Int. 2012;12 Suppl 1:77–87. doi:10.1111/j.1447-0594.2011.00815.x.PubMedCrossRef

27.

Chacko KM, Bauer TA, Dale RA, Dixon JA, Schrier RW, Estacio RO. Heart rate recovery predicts mortality and cardiovascular events in patients with type 2 diabetes. Med Sci Sports Exerc. 2008;40:288–95. doi:10.1249/mss.0b013e31815c4844.PubMedCrossRef

28.

•• Church TS, Cheng YJ, Earnest CP, Barlow CE, Gibbons LW, Priest EL, et al. Exercise capacity and body composition as predictors of mortality among men with diabetes. Diabetes Care. 2004;27:83–8. One of several papers showing that a low aerobic fitness level is an important predictor of mortality in people with type 2 diabetes.PubMedCrossRef

29.

Curtis JM, Horton ES, Bahnson J, Gregg EW, Jakicic JM, Regensteiner JG, et al. Prevalence and predictors of abnormal cardiovascular responses to exercise testing among individuals with type 2 diabetes: the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010;33:901–7. doi:10.2337/dc09-1787.PubMedCrossRef

30.

Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481–6. doi:10.2337/dc10-2415.PubMedCrossRef

31.

Belalcazar LM, Reboussin DM, Haffner SM, Hoogeveen RC, Kriska AM, Schwenke DC, et al. A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010;33:2297–303. doi:10.2337/dc10-0728.PubMedCrossRef

32.

•• Wing RR. Look Ahead Research Group, Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170:1566–75. doi:10.1001/archinternmed.2010.334. An important outcome paper from Look AHEAD showing that lifestyle intervention does not appear to impact CVD event rates in people with type 2 diabetes.PubMedCrossRef

33.

Kirk A, Mutrie N, MacIntyre P, Fisher M. Effects of a 12-month physical activity counselling intervention on glycaemic control and on the status of cardiovascular risk factors in people with Type 2 diabetes. Diabetologia. 2004;47:821–32. doi:10.1007/s00125-004-1396-5.PubMedCrossRef

34.

Balducci S, Zanuso S, Cardelli P, Salvi L, Mazzitelli G, Bazuro A, et al. Changes in physical fitness predict improvements in modifiable cardiovascular risk factors independently of body weight loss in subjects with type 2 diabetes participating in the Italian Diabetes and Exercise Study (IDES). Diabetes Care. 2012;35:1347–54. doi:10.2337/dc11-1859.PubMedCrossRef

35.

Johnson ST, Bell GJ, McCargar LJ, Welsh RS, Bell RC. Improved cardiovascular health following a progressive walking and dietary intervention for type 2 diabetes. Diabetes Obes Metab. 2009;11:836–43. doi:10.1111/j.1463-1326.2009.01050.x.PubMedCrossRef

36.

Lima LC, Assis GV, Hiyane W, Almeida WS, Arsa G, Baldissera V, et al. Hypotensive effects of exercise performed around anaerobic threshold in type 2 diabetic patients. Diabetes Res Clin Pract. 2008;81:216–22. doi:10.1016/j.diabres.2008.04.019.PubMedCrossRef

37.

Madden KM, Lockhart C, Cuff D, Potter TF, Meneilly GS. Short-term aerobic exercise reduces arterial stiffness in older adults with type 2 diabetes, hypertension, and hypercholesterolemia. Diabetes Care. 2009;32:1531–5. doi:10.2337/dc09-0149.PubMedCrossRef

38.

Tudor-Locke C, Bell RC, Myers AM, Harris SB, Ecclestone NA, Lauzon N, et al. Controlled outcome evaluation of the First Step Program: a daily physical activity intervention for individuals with type II diabetes. Int J Obes Relat Metab Disord. 2004;28:113–9. doi:10.1038/sj.ijo.0802485.PubMedCrossRef

39.

Eriksson MK, Franks PW, Eliasson M. A 3-year randomized trial of lifestyle intervention for cardiovascular risk reduction in the primary care setting: the Swedish Bjorknas study. PLoS One. 2009;4:e5195. doi:10.1371/journal.pone.0005195.PubMedCrossRef

40.

Lindahl B, Nilsson TK, Borch-Johnsen K, Roder ME, Soderberg S, Widman L, et al. A randomized lifestyle intervention with 5-year follow-up in subjects with impaired glucose tolerance: pronounced short-term impact but long-term adherence problems. Scand J Public Health. 2009;37:434–42. doi:10.1177/1403494808101373.PubMedCrossRef

41.

• Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, et al. Action to control cardiovascular risk in diabetes study group, effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59. doi:10.1056/NEJMoa0802743. An important drug trial showing that targeted glucose-lowering interventions do not diminish CVD event rates in people with type 2 diabetes.PubMedCrossRef

42.

Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. Diabetes Prevention Program Research Group, 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–86. doi:10.1016/s0140-6736(09)61457-4.PubMedCrossRef

43.

Smart-Halajko MC, Kelley-Hedgepeth A, Montefusco MC, Cooper JA, Kopin A, McCaffrey JM, et al. ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels in Non-Hispanic White Americans from the Look AHEAD Clinical Trial. BMC Med Genet. 2011;12:89. doi:10.1186/1471-2350-12-89.PubMedCrossRef

44.

McCaffery JM, Papandonatos GD, Peter I, Huggins GS, Raynor HA, Delahanty LM, et al. Obesity susceptibility loci and dietary intake in the Look AHEAD Trial. Am J Clin Nutr. 2012;95:1477–86. doi:10.3945/ajcn.111.026955.PubMedCrossRef

45.

Peter I, McCaffery JM, Kelley-Hedgepeth A, Hakonarson H, Reis S, Wagenknecht LE, et al. Association of type 2 diabetes susceptibility loci with 1-year weight loss in the look AHEAD clinical trial. Obesity. 2012;20:1675–82. doi:10.1038/oby.2012.11.PubMedCrossRef

46.

Cardoso CR, Maia MD, de Oliveira FP, Leite NC, Salles GF. High fitness is associated with a better cardiovascular risk profile in patients with type 2 diabetes mellitus. Hypertens Res. 2011;34:856–61. doi:10.1038/hr.2011.50.PubMedCrossRef

47.

Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93. doi:10.1056/NEJMoa021778.PubMedCrossRef

48.

Hu G, Jousilahti P, Barengo NC, Qiao Q, Lakka TA, Tuomilehto J. Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes. Diabetes Care. 2005;28:799–805.PubMedCrossRef

49.

Jakicic JM, Jaramillo SA, Balasubramanyam A, Bancroft B, Curtis JM, Mathews A, et al. Effect of a lifestyle intervention on change in cardiorespiratory fitness in adults with type 2 diabetes: results from the Look AHEAD Study. Int J Obes. 2009;33:305–16. doi:10.1038/ijo.2008.280.CrossRef

50.

Jonker JT, De Laet C, Franco OH, Peeters A, Mackenbach J, Nusselder WJ. Physical activity and life expectancy with and without diabetes: life table analysis of the Framingham Heart Study. Diabetes Care. 2006;29:38–43.PubMedCrossRef

51.

Lau C, Vistisen D, Toft U, Tetens I, Glumer C, Pedersen O, et al. The effects of adding group-based lifestyle counselling to individual counselling on changes in plasma glucose levels in a randomized controlled trial: the Inter99 study. Diabetes Metab. 2011;37:546–52. doi:10.1016/j.diabet.2011.06.001.PubMedCrossRef

52.

Lin CC, Li CI, Liu CS, Lin WY, Fuh MM, Yang SY, et al. Impact of lifestyle-related factors on all-cause and cause-specific mortality in patients with type 2 diabetes: the Taichung Diabetes Study. Diabetes Care. 2012;35:105–12. doi:10.2337/dc11-0930.PubMedCrossRef

53.

Menard J, Payette H, Baillargeon JP, Maheux P, Lepage S, Tessier D, et al. Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. CMAJ. 2005;173:1457–66. doi:10.1503/cmaj.050054.PubMed

54.

Regensteiner JG, Bauer TA, Reusch JE, Quaife RA, Chen MY, Smith SC, et al. Cardiac dysfunction during exercise in uncomplicated type 2 diabetes. Med Sci Sports Exerc. 2009;41:977–84. doi:10.1249/MSS.0b013e3181942051.PubMedCrossRef

55.

Tanasescu M, Leitzmann MF, Rimm EB, Hu FB. Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation. 2003;107:2435–9. doi:10.1161/01.cir.0000066906.11109.1f.PubMedCrossRef

Title: Exercise and Diabetes-Related Cardiovascular Disease: Systematic Review of Published Evidence from Observational Studies and Clinical Trials
Authors: Robert W. Koivula
Åsa B. Tornberg
Paul W. Franks
Publication date: 01-06-2013
Publisher: Current Science Inc.
Published in: Current Diabetes Reports / Issue 3/2013
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-013-0373-0

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

Nuclear Factor (Erythroid-Derived 2)-Like-2 Factor (Nrf2), a Key Regulator of the Antioxidant Response to Protect Against Atherosclerosis and Nonalcoholic Steatohepatitis

The Place of GLP-1–Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists

Diabetes Mellitus and Inflammation

Do Statins Cause Diabetes?

Is the Risk and Nature of CVD the Same in Type 1 and Type 2 Diabetes?

Diabetes Mellitus and Osteoporosis

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage